1. Home
  2. AIDX

as of 11-19-2026 3:54pm EST

$0.18
$0.00
-1.90%
Stocks Health Care Precision Instruments Nasdaq

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

Founded: 2000 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 2.9M IPO Year: 2025
Target Price: N/A AVG Volume (30 days): 206.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.62 EPS Growth: 34.48
52 Week Low/High: $0.18 - $18.96 Next Earning Date: 11-16-2026
Revenue: $2,045,133 Revenue Growth: 16.71%
Revenue Growth (this year): 44.2% Revenue Growth (next year): 95.73%
P/E Ratio: -0.30 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K

Nov 16, 2026

0001213900-26-120734

EX-99.1

2 ea031249801ex99-1.htm

PRESS RELEASE ISSUED ON NOVEMBER 16, 2026

Exhibit 99.1

20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates

OneTest™ Revenue Increased 4.1% to $1.36 Million for First Nine Months of 2026, with Gross Margin Expanding to 32.8%

Vermont Executes Two-Year Firefighter Cancer

Screening Contract with Testing Expected to Contribute Revenue in Q4

New Laboratory Franchise Model and 2027 Licensing Plans Aim to Broaden OneTest™ Distribution

Cash of $3.63 Million and No Outstanding Debt as of September 30, 2026

GAITHERSBURG, MD — November 16, 2026 — 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the third quarter ended September 30, 2026.

Third Quarter and Recent Operational Highlights

●OneTest™ revenue increased 4.1% to $1.36 million for the first nine months of 2026, representing 92.8% of total revenue.

●OneTest™ gross profit increased 15.6% to $0.45 million for the first nine months of 2026, with gross margin expanding to 32.8% from 29.5%.

●Third quarter revenue was $0.38 million, compared to $0.42 million in the prior year period, reflecting the timing of firefighter cancer screening programs.

●Vermont executed a two-year contract specifying OneTest™ Premium for its statewide cancer screening program covering approximately 4,500 firefighters. Testing is expected to begin contributing to revenue in Q4 2026.

●Continued OneTest™ testing through Maryland's state-funded firefighter cancer screening program, with 18 groups of fire departments awarded more than $520,000 in grants.

●Introduced a OneTest™ laboratory franchise model to expand distribution through regional laboratories under a royalty-based structure.

●Announced plans to begin licensing its patented protein tumor marker testing technology to laboratories in the U.S. and internationally in 2027.

●Entered into $1.30 million of non-cancelable customer contracts during the first nine months of 2026.

●Cash and cash equivalents totaled $3.63 million as of September 30, 2026, with no outstanding borrowings.

Management Commentary

President and Chief Executive Officer Jonathan Cohen commented, “OneTest™ revenue grew 4.1% through the first nine months of the year, with gross profit increasing 15.6%. While third quarter revenue was below the prior year, much of this reflected the timing of our state-funded firefighter cancer screening programs. Maryland completed a significant portion of its testing in the second quarter, while the start of Vermont’s program shifted into the fourth quarter. Vermont has now executed its two-year contract, and we expect testing to begin contributing to revenue before year-end.”

“We are also working on new ways to reach more customers. Our franchise model would allow established regional laboratories to offer OneTest™ in their markets, without requiring us to build a national sales force. We have received preliminary interest from laboratories in the United States and plan to begin licensing our protein tumor marker approach to clinical laboratories in 2027.”

“With more than 25,000 firefighters screened to date, we are continuing to build the real-world evidence to support our regulatory strategy. We believe recent developments in the MCED testing industry are encouraging, and we remain focused on our goal of obtaining FDA authorization and Medicare reimbursement for OneTest™ for Cancer by the end of 2028,” concluded Cohen.

Chief Financial Officer Alan Bergman added, “We ended the third quarter with $3.63 million in cash and no outstanding borrowings, compared to $1.03 million in cash at year-end 2025. Our net loss narrowed to $1.38 million from $1.51 million in the second quarter, while operating expenses declined 4.0% sequentially.”

“Gross margin was lower this quarter due to reduced testing volume, but our laboratory has the capacity to support additional testing without a corresponding increase in certain operating costs. As testing under the Vermont contract and other programs increases, we expect to benefit from better utilization of our existing laboratory capacity while continuing to manage expenses,” concluded Bergman.

Third Quarter 2026 Financial Results

Total revenue for the three months ended September 30, 2026 was $0.38 million, compared to $0.42 million in the prior year period. OneTest™ revenue was $0.35 million, compared to $0.36 million, and represented 92.8% of total revenue, up from 86.3%. The decrease primarily reflected the timing of state-funded firefighter cancer screening programs.

Total cost of revenue was $0.28 million, compared to $0.27 million in the prior year period.

Gross profit was $0.10 million, compared to $0.15 million in the prior year period. Gross margin was 25.5%, compared to 34.7%, reflecting l

2026
Q2

Q2 2026 Earnings

8-K

Aug 17, 2026

0001213900-26-090746

EX-99.1

2 ea030215301ex99-1.htm

PRESS RELEASE ISSUED ON AUGUST 17, 2026

Exhibit 99.1

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Total Revenue Increased 37% to $0.7 Million and Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5%

Best Quarter of Multi-Cancer

Early Detection Testing, with OneTest™ Revenue Up 47% Year-Over-Year to $0.7 Million

Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter

Gaithersburg, MD - August 17, 2026 - 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the second quarter ended June 30, 2026.

Second Quarter & Subsequent 2026 Operational Highlights

●Total revenue increased 36.5% to $0.7 million for Q2 2026, as compared to $0.5 million for Q2 2025, with OneTest™ accounting for 95.3% of total revenue in the quarter, up from 88.4% in the prior year period.

●Revenue from the Company’s OneTest™ family of blood tests, led by OneTest™ for Cancer, its Multi-Cancer Early Detection (“MCED”) blood test, increased 47.1% to $0.7 million for Q2 2026, as compared to $0.5 million for Q2 2025. The Company believes Q2 2026 represented its strongest quarter of MCED testing.

●Gross profit increased 86.6% to $0.3 million for Q2 2026, as compared to $0.2 million for Q2 2025, while gross margin expanded to 41.7% from 30.5%, reflecting improved absorption of fixed laboratory costs across a higher volume of OneTest™ tests.

●State-funded firefighter cancer screening programs continued to gain momentum. In May, the State of Vermont selected OneTest™ for a 12-month statewide initiative to screen up to 4,500 firefighters, while Maryland fire departments were awarded $520,000 for OneTest™ cancer screenings. The Company expects these programs to generate more than $1.0 million of revenue through the end of 2026.

●The Company expects to have tested more than 35,000 firefighters by the end of 2026, building a body of real-world evidence intended to support its regulatory and reimbursement strategy.

●Received orders from 29 new accounts during the second quarter, including occupational and preventive health companies, fire departments and primary care physician practices. Growth has continued into the third quarter across fire department, occupational health, military service and physician practice markets.

●Executed a purchase agreement with the TF – 7294 Foundation that expands access to OneTest™ for Cancer within the U.S. Intelligence Community.

●Received a first commercial order from BodyMetRX, extending the OneTest™ for Cancer footprint into the health optimization and wellness market.

●Maintained strong repeat business from existing customers, with Clayton County, Georgia beginning its seventh year of OneTest™ for Cancer screening, and continued to grow its enterprise pipeline entering the second half of 2026.

●Launched a three-month retail pilot with Giant Food for OneTest for Longevity™, making the Company’s inflammatory and cardiometabolic biomarker testing available through participating Giant Food stores via pharmacy-based blood collection and at-home self-collection kits.

●Cash and cash equivalents totaled $4.5 million as of June 30, 2026, compared to $1.0 million as of December 31, 2025.

●Issued an additional 1,000 shares of Series E convertible preferred stock on June 16, 2026 for gross proceeds of $1.0 million, bringing total Series E proceeds to $6.0 million for the first half of 2026 under a preferred purchase agreement pursuant to which up to $40.0 million in capital may be raised in multiple tranches, subject to 20/20 meeting certain conditions.

●Subsequent to the first quarter, on April 10, 2026, all principal and accrued interest outstanding under the Company’s secured convertible promissory notes was exchanged for 583 shares of Series E convertible preferred stock, eliminating all convertible note debt from the Company’s balance sheet as of June 30, 2026.

●Subsequent to quarter end, on July 16, 2026, the Company entered into a standstill agreement with Streeterville under which Streeterville agreed that, for 120 days, it will not convert shares of Series E convertible preferred stock into common stock unless the common stock trades at least 10% above the “Minimum Price” as defined in Nasdaq Rule 5635.

●Accounts receivable increased to approximately $0.3 million as of June 30, 2026, compared to $0.2 million as of December 31, 2025, reflecting higher MCED testing volume late in the quarter.

●Hosted the inaugural session of a new monthly investor webinar series on July 1, 2026, focused on the Company’s Medicare strategy for OneTest™ and its serial biomarker tracking

2026
Q1

Q1 2026 Earnings

8-K

May 20, 2026

0001213900-26-059526

Transcript text not available. View on SEC.gov →

Share on Social Networks: